EcoDrugPlus

Glutamate Ionotropic Receptor Kainate Type Subunit 3

Ensembl ID : ENSBSLG00000022127
Gene Symbol: GRIK3
3 Cross references
257 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 4

Ensembl ID : ENSBSLG00000003924
Gene Symbol: GRIK4
3 Cross references
245 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 5

Ensembl ID : ENSBSLG00000005670
Gene Symbol: GRIK5
3 Cross references
263 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 5

Ensembl ID : ENSBSLG00000005172
Gene Symbol: GRIK5
3 Cross references
258 Possible Orthologues:

Glutamate Metabotropic Receptor 2

Ensembl ID : ENSBSLG00000016594
Gene Symbol: GRM2
3 Cross references
210 Possible Orthologues:

Glutamate Metabotropic Receptor 4

Ensembl ID : ENSBSLG00000015615
Gene Symbol: GRM4
3 Cross references
214 Possible Orthologues:

Glutamate Metabotropic Receptor 5

Ensembl ID : ENSBSLG00000015914
Gene Symbol: GRM5
3 Cross references
216 Possible Orthologues:

Glutamate Receptor 1-Like

Ensembl ID : ENSBSLG00000022444
Gene Symbol: LOC114865072
3 Cross references
252 Possible Orthologues:

Glutamate Receptor 1-Like

Ensembl ID : ENSBSLG00000002437
Gene Symbol: LOC114869096
2 Cross references
250 Possible Orthologues:

Glutamate Receptor 2-Like

Ensembl ID : ENSBSLG00000018711
Gene Symbol: LOC114851284
3 Cross references
243 Possible Orthologues:

Glutamate Receptor 3-Like

Ensembl ID : ENSBSLG00000006873
Gene Symbol: LOC114869567
2 Cross references
254 Possible Orthologues:

Glutamate Receptor 4

Ensembl ID : ENSBSLG00000013482
Gene Symbol: LOC114869268
2 Cross references
252 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).